Skip to main content

Table 2 Relationship between treatment response and clinicopathological factors

From: High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area

 

Treatment response

Multi-variates

 

CR/PR

SD/PD

P

OR

(95%CI)

P

Age

     

   ≦50

15 (68.2%)

7 (31.8%)

0.844

1

 

   > 50

26 (74.3%)

9 (25.7%)

 

0.53 (0.07, 3.65)

0.520

Gender

     

   male

39 (70.9%)

16 (29.1%)

1.000

1

 

   female

2 (100%)

0 (0%)

 

Indeterminate

1.000

Tumor Site

     

   oral cavity

15 (62.5%)

9 (37.5%)

0.049*

1

 

   oropharynx

14 (66.7%)

7 (33.3%)

 

1.29 (0.21, 7.70)

0.778

   hypopharynx/larynx

12 (100%)

0

 

Indeterminate

0.998

Stage

     

   IVa

10 (100%)

0 (0%)

0.048*

1

 

   IVb

31 (66.0%)

16 (34.0%)

 

Indeterminate

0.998

T stage

     

   1/2

6 (100%)

0 (0%)

0.170

1

 

   3/4

35 (68.6%)

16 (31.4%)

 

Indeterminate

0.999

N stage

     

   negative

8 (66.7%)

4 (25.0%)

0.732

1

 

   positive

33 (73.3%)

12 (26.7%)

 

0.75 (0.06, 8.54)

0.818

Radiation

     

   ≦6000 cGy

14 (70.0%)

6 (30.0%)

1.000

1

 

   > 6000 cGy

27 (75.7%)

10 (24.3%)

 

0.22 (0.02, 2.43)

0.222

Alcohol drinking

     

   never

9 (81.8%)

2 (18.2%)

0.710

1

0.120

   yes

32 (69.6%)

14 (30.4%)

 

0.08 (0.004, 1.89)

 

   Smoking

     

   never

7 (77.8%)

2 (22.2%)

1.000

1

 

   yes

34 (70.8%)

14 (29.2%)

 

2.97 (0.10, 86.59)

0.526

Betel nuts

     

   never

16 (80.0%)

4 (20.0%)

0.491

1

 

   yes

25 (67.6%)

12 (32.4%)

 

0.38 (0.03, 4.55)

0.452

ERCC1

     

   low expression

28 (90.3%)

3 (9.7%)

0.002*

1

 

   high expression

13 (20.0%)

13 (50.0%)

 

0.07 (0.009, 055).

0.012*

  1. CR, complete response; PR, partial response; SD, stable disease; PD, disease progression; RTO, radiotherapy; OR, odds ratio; CI, confidence interval
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us